| rqh1+, a fission yeast gene related to the Bloom‘s and Werner's syndrome genes, is required for reversible S phase arrest E Stewart, CR Chapman, F Al‐Khodairy, AM Carr, T Enoch The EMBO Journal, 1997 | 432 | 1997 |
| Genetic discrimination: emerging ethical challenges in the context of advancing technology CR Chapman, KS Mehta, B Parent, AL Caplan Journal of Law and the Biosciences 7 (1), lsz016, 2020 | 55 | 2020 |
| Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing M Angrist, R Barrangou, F Baylis, C Brokowski, G Burgio, A Caplan, ... The CRISPR journal 3 (5), 332-349, 2020 | 28 | 2020 |
| What compassionate use means for gene therapies CR Chapman, KI Moch, A McFadyen, L Kearns, T Watson, P Furlong, ... Nature Biotechnology, 2019 | 23 | 2019 |
| Requirement of sequences outside the conserved kinase domain of fission yeast Rad3p for checkpoint control CR Chapman, ST Evans, AM Carr, T Enoch Molecular biology of the cell 10 (10), 3223-3238, 1999 | 19 | 1999 |
| Federal Right to Try: where is it going? K Folkers, C Chapman, B Redman Hastings Center Report 49 (2), 26-36, 2019 | 17 | 2019 |
| Gene therapy companies have an ethical obligation to develop expanded access policies L Kearns, CR Chapman, KI Moch, AL Caplan, T Watson, A McFadyen, ... Molecular Therapy 29 (4), 1367-1369, 2021 | 14 | 2021 |
| Oversight of right‐to‐try and expanded access requests for off‐trial access to investigational drugs CR Chapman, J Eckman, AS Bateman‐House Ethics & Human Research 42 (1), 2-13, 2020 | 14 | 2020 |
| The quest for compensation for research-related injury in the United States: a new proposal CR Chapman, S Sukumaran, GT Tsegaye, Y Shevchenko, AL Caplan The Journal of Law, Medicine & Ethics 47 (4), 732-747, 2019 | 9 | 2019 |
| Single-patient expanded access requests: IRB professionals’ experiences and perspectives CR Chapman, JA Shearston, KMB Folkers, BK Redman, A Caplan, ... AJOB Empirical Bioethics 10 (2), 88-99, 2019 | 8 | 2019 |
| Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic … CR Chapman Journal of Community Genetics 14 (5), 441-452, 2023 | 6 | 2023 |
| A survey of pediatric hematologists/oncologists’ perspectives on single patient Expanded Access and Right to Try CR Chapman, HM Belli, D Leach, LD Shah, A Bateman-House Medicine Access@ Point of Care 5, 23992026211005991, 2021 | 6 | 2021 |
| Ethical challenges in autism genomics: Recommendations for researchers HM Natri, CR Chapman, S Heraty, P Dwyer, N Walker, SK Kapp, HA Dron, ... European Journal of Medical Genetics, 104810, 2023 | 2 | 2023 |
| Preapproval Nontrial Access and Off-Label Use: Do They Meet Criteria for Dual-Deviation Review? CR Chapman, KMB Folkers, A McFadyen, LD Shah, A Bateman-House The American Journal of Bioethics 19 (6), 22-25, 2019 | 2 | 2019 |
| Primary duty is to communicate moment-in-time nature of genetic variant interpretation CR Chapman Journal of Medical Ethics 49 (12), 817-818, 2023 | 1 | 2023 |
| Protect newborn screening programs K Owens, C Chapman, A Caplan Science 379 (6639), 1307-1308, 2023 | 1 | 2023 |
| How should physicians respond when they learn patients are using unapproved gene editing interventions? CR Chapman, AL Caplan AMA Journal of Ethics 21 (12), 1021-1028, 2019 | 1 | 2019 |
| Bolstering trust in the human papillomavirus vaccine through improved communication in the Vaccine Information Statement C Constable, CR Chapman Vaccine 37 (31), 4241-4242, 2019 | 1 | 2019 |
| Immunisation for the Sake of the ‘Herd’ CR Chapman, AL Caplan eLS, 1-7, 2018 | 1 | 2018 |
| A Case for More Generous Compensation for Human Research Subjects in Non-Therapeutic Research C Chapman Voices in Bioethics, 2015 | 1 | 2015 |
